Maksym Galkin
Maksym Galkin received his Master's degree in Biochemistry from Kyiv National University in 2014. After that, he worked at the Department of Neurochemistry at the Palladin Institute of Biochemistry. He received his PhD degree from Charles University (Prague, Czech Republic), where he defended his dissertation on the development of a method for testing selective inhibitors of alpha-synuclein aggregation, a protein that plays a key role in the development of Parkinson's disease. The research was carried out at the Institute of Organic Chemistry and Biochemistry (IOCB Prague) of the Czech Academy of Sciences. He is currently working at the Danish Cancer Institute (DCI), focusing on the development of methods to inhibit protein aggregation.
ORCID: 0000-0002-5953-1725, Scopus, ResearchGate.
1. M. Galkin, A. Priss, Y. Kyriukha, V. Shvadchak. Navigating α-Synuclein Aggregation Inhibition: Methods, Mechanisms, and Molecular Targets. Chem Rec, 2023, Nov 2:e202300282, doi: 10.1002/tcr.202300282
2. M. Galkin, O. Topcheva, A. Priss, T. Borisova, and V. V. Shvadchak. Dopamine-Induced Oligomers of α-Synuclein Inhibit Amloid Fibril Growth and Show No Toxicity. ACS Chemical Neuroscience 2023 14 (11), 2027-2034, doi: 10.1021/acschemneuro.2c00815
3. Poryvai A, Galkin M, Shvadchak V, Slanina T. Red-Shifted Water-Soluble BODIPY Photocages for Visualisation and Controllable Cellular Delivery of Signaling Lipids. Angew Chem Int Ed Engl. 2022 May 16:e202205855.
4. Galkin M., Priss A., Topcheva O., Yushchenko D.A., Shvadchak V.V. FRET-based assay for intracellular evaluation of α-synuclein aggregation inhibitors. Journal of Neurochemistry, 2021, 00, 1-12.
